$SMTI
Sanara Medtech Inc Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017272 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$15.75M	$15.52M	$7.811M
YoY Change	62.89%	98.71%	-30.79%
Cost Of Revenue	$2.188M	$2.126M	$805.1K
YoY Change	128.32%	164.03%	71.29%
Gross Profit	$13.57M	$13.40M	$7.006M
YoY Change	55.7%	91.21%	54.32%
Gross Profit Margin	86.11%	86.31%	89.69%
Selling, General & Admin	$13.81M	$12.97M	$9.376M
YoY Change	32.44%	38.33%	73.3%
% of Gross Profit	101.81%	96.81%	133.82%
Research & Development	$1.177M	$1.317M	$204.6K
YoY Change	10.32%	543.73%	70.53%
% of Gross Profit	8.68%	9.83%	2.92%
Depreciation & Amortization	$108.5K	$107.7K	$202.8K
YoY Change	-73.67%	-46.89%	125.28%
% of Gross Profit	0.8%	0.8%	2.89%
Operating Expenses	$15.43M	$14.61M	$9.783M
YoY Change	29.6%	49.37%	74.08%
Operating Profit	-$1.866M	-$1.216M	-$2.777M
YoY Change	-41.58%	-56.2%	157.12%
Interest Expense		$6.00
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$6.00	-$379.6K
YoY Change		-100.0%
Pretax Income	-$1.866M	-$1.216M	-$3.157M
YoY Change	-42.72%	-61.47%	167.5%
Income Tax
% Of Pretax Income
Net Earnings	-$1.828M	-$1.178M	-$3.157M
YoY Change	-43.9%	-62.68%	166.74%
Net Earnings / Revenue	-11.6%	-7.59%	-40.41%
Basic Earnings Per Share	-$0.22	-$0.14	-$0.41
Diluted Earnings Per Share	-$0.22	-$0.14	-$411.4K
COMMON SHARES
Basic Shares Outstanding	8.383M shares	8.377M shares	7.606M shares
Diluted Shares Outstanding	8.226M shares	8.174M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.060M	$7.286M	$16.14M
YoY Change	-52.2%	-54.86%	-40.93%
Cash & Equivalents	$6.060M	$7.286M	$16.14M
Short-Term Investments
Other Short-Term Assets	$485.7K	$1.748M	$624.9K
YoY Change	-34.31%	179.77%	20.18%
Inventory	$4.421M	$3.432M	$2.171M
Prepaid Expenses
Receivables	$7.211M	$6.541M	$3.555M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$18.18M	$19.01M	$22.49M
YoY Change	-8.32%	-15.5%	-28.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.240M	$1.336M	$1.934M
YoY Change	-18.06%	-30.93%	-7.9%
Goodwill	$3.602M	$3.602M
YoY Change
Intangibles	$30.14M	$30.84M
YoY Change	38.55%
Long-Term Investments	$3.084M	$3.084M	$4.888M
YoY Change	0.0%	-36.9%	205.48%
Other Assets
YoY Change
Total Long-Term Assets	$40.10M	$40.96M	$11.44M
YoY Change	50.47%	258.05%	52.94%
TOTAL ASSETS
Total Short-Term Assets	$18.18M	$19.01M	$22.49M
Total Long-Term Assets	$40.10M	$40.96M	$11.44M
Total Assets	$58.28M	$59.97M	$33.93M
YoY Change	25.39%	76.72%	-13.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.113M	$1.821M	$981.2K
YoY Change	51.84%	85.62%	165.19%
Accrued Expenses	$8.069M	$8.094M	$4.250M
YoY Change	47.99%	90.46%	53.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.881M	$10.60M	$5.231M
YoY Change	42.58%	102.67%	67.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.654M	$6.028M	$187.0K
YoY Change	43.29%	3122.63%	-54.38%
Total Long-Term Liabilities	$7.433M	$7.887M	$187.0K
YoY Change	81.43%	4116.63%	-54.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.881M	$10.60M	$5.231M
Total Long-Term Liabilities	$7.433M	$7.887M	$187.0K
Total Liabilities	$17.31M	$18.49M	$4.902M
YoY Change	57.01%	277.13%	61.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.74M	-$24.91M
YoY Change	23.46%
Common Stock	$67.89M	$66.54M
YoY Change	17.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.15M	$41.62M	$29.03M
YoY Change
Total Liabilities & Shareholders Equity	$58.28M	$59.97M	$33.93M
YoY Change	25.39%	76.72%	-13.04%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.828M	-$1.178M	-$3.157M
YoY Change	-43.9%	-62.68%	166.74%
Depreciation, Depletion And Amortization	$108.5K	$107.7K	$202.8K
YoY Change	-73.67%	-46.89%	125.28%
Cash From Operating Activities	-$1.720M	-$1.741M	-$2.112M
YoY Change	48.99%	-17.57%	67.66%
INVESTING ACTIVITIES
Capital Expenditures	$12.94K	$27.71K	-$44.70K
YoY Change	-100.62%	-161.98%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$650.00	-$249.7K
YoY Change		-100.26%	-58.39%
Cash From Investing Activities	-$12.94K	-$27.06K	-$294.4K
YoY Change	-99.38%	-90.81%	-50.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	506.6K	$95.81K	-102.9K
YoY Change	-330.27%	-193.08%	-100.36%
NET CHANGE
Cash From Operating Activities	-1.720M	-$1.741M	-2.112M
Cash From Investing Activities	-12.94K	-$27.06K	-294.4K
Cash From Financing Activities	506.6K	$95.81K	-102.9K
Net Change In Cash	-1.226M	-$1.673M	-2.510M
YoY Change	-64.6%	-33.36%	-109.34%
FREE CASH FLOW
Cash From Operating Activities	-$1.720M	-$1.741M	-$2.112M
Capital Expenditures	$12.94K	$27.71K	-$44.70K
Free Cash Flow	-$1.733M	-$1.769M	-$2.068M
YoY Change	-285.21%	-14.45%	64.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000714256
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities		usd
CY2022Q1	us-gaap	Interest Expense InterestExpense		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022Q1	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities		usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2023Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments		usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q1	SMTI	Right Of Use Assets Obtained In Exchange For Lease Obligations RightOfUseAssetsObtainedInExchangeForLeaseObligations		usd
CY2023Q1	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Additions BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAdditions		usd
CY2023Q1	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Settlements BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationSettlements		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39678
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
CY2023Q1	dei	City Area Code CityAreaCode	(817)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	529-2300
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	SMTI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8382616	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7286437	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8958995	usd
CY2023Q1	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2022Q4	SMTI	Royalty Receivable RoyaltyReceivable	99594	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	3431704	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3549000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1748338	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1104611	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	19007678	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	20616509	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1335817	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2099021	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	806402	usd
CY2023Q1	us-gaap	Goodwill Goodwill	3601781	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30838779	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31509980	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	40959676	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	40418877	usd
CY2023Q1	us-gaap	Assets Assets	59967354	usd
CY2022Q4	us-gaap	Assets Assets	61035386	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2031701	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2144475	usd
CY2023Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	5808959	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7758284	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	686406	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1162880	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	253381	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	313933	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10601797	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12806309	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6027598	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6003811	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1859189	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	505291	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7886787	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6509102	usd
CY2023Q1	us-gaap	Liabilities Liabilities	18488584	usd
CY2022Q4	us-gaap	Liabilities Liabilities	19315411	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8385027	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8385027	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8299957	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8299957	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	8385	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8300	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	66529380	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65213987	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24913011	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23394757	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	41624754	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	41827530	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-145984	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-107555	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59967354	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61035386	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15521917	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7811223	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2125659	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	805081	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	13396258	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	7006142	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12969069	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9375630	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1317324	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	204637	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	778875	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	202747	usd
CY2023Q1	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	452687	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14612581	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	9783014	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1216323	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2776872	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	6	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-379633	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3156505	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38429	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27181	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1177900	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3129324	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8173784	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7606450	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1623118	usd
CY2022Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-102931	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3156505	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28515686	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	597305	usd
CY2023Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-655942	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1033761	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3156505	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	778875	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	202747	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2501	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	36000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	15000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	30511	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	71819	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	597305	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	584935	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	76545	usd
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	57688	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q1	SMTI	Change In Fair Value Of Earnout Liabilities ChangeInFairValueOfEarnoutLiabilities	452687	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-352102	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	563034	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-74602	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	16492	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-86785	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	194956	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	361719	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-292394	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	405360	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	491220	usd
CY2023Q1	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-10747	usd
CY2022Q1	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-103970	usd
CY2023Q1	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	-112774	usd
CY2022Q1	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	234141	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1949325	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-409599	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-75817	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1741313	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2112478	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27705	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44697	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	650	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	345	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27055	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-294352	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	751752	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-655942	usd
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-102931	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95810	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-102931	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1672558	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2509761	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18652841	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7286437	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16143080	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	6	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	282010	usd
CY2023Q1	SMTI	Right Of Use Assets Obtained In Exchange For Lease Obligations RightOfUseAssetsObtainedInExchangeForLeaseObligations	1369164	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_znPnUIgU7PGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_820_zN6TqSfSDEv1">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority-owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies contributes to the Company’s overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zA8N9vnZVx2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zM5FyGppTOlh">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15521917	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7811223	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	36000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	15000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	304994	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	269850	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3905	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4761	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	30511	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	71819	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	462521	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	523832	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2183478	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2156422	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	847661	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	739986	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1335817	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2023Q1	us-gaap	Depreciation Depreciation	107674	usd
CY2022Q1	us-gaap	Depreciation Depreciation	92724	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7166691	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-452687	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6714004	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y3M18D
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	671201	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	110023	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2085604	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2780806	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2780806	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2763550	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2649698	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2616456	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	15161859	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	30838779	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q1	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2023Q1	us-gaap	Investments Investments	3084278	usd
CY2022Q4	us-gaap	Investments Investments	3084278	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2099021	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2112570	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	88419	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	63407	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	87691	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	63889	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	266473	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	424753	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	450551	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	365911	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	297947	usd
CY2023Q1	SMTI	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	604050	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2705374	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	592804	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2112570	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	253381	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1859189	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0749	pure
CY2023Q1	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	50250	usd
CY2023Q1	SMTI	Annual Royalty Obligation AnnualRoyaltyObligation	4020	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	74781	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	3125667	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	597305	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	584935	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4803372	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	181102	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.89
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	76518	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	41.43
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	73996	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	19.88
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1737	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	25.61
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	181887	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	31.77
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146191	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.65
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146191	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.65
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	146191	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.65
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2022Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2023Q1	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2023Q1	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
CY2023Q1	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-017272-index-headers.html	Edgar Link	pending
0001493152-23-017272-index.html	Edgar Link	pending
0001493152-23-017272.txt	Edgar Link	pending
0001493152-23-017272-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20230331.xsd	Edgar Link	pending
smti-20230331_cal.xml	Edgar Link	unprocessable
smti-20230331_lab.xml	Edgar Link	unprocessable
smti-20230331_def.xml	Edgar Link	unprocessable
smti-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara Medtech Inc Stock $smti

2023 Q2 Form 10-Q Financial Statement

#000149315223017272 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara Medtech Inc Stock $smti

2023 Q2 Form 10-Q Financial Statement

#000149315223017272 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara Medtech Inc Stock $smti